CoChat

A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease

Open access
Maciejewska, Karolina, Czarnecka, Kamila, Szymański, Paweł · 2021 · Pharmacological Reports

The DOI matches its Crossref record; 175 of the 176 references it cites were found in a registry or an index.

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system (CNS) leading to mental deterioration and devastation, and eventually a fatal outcome. AD affects mostly the elderly. AD is frequently accompanied by hypercholesterolemia, hypertension, atherosclerosis, and diabetes mellitus, and these are significant risk factors of AD. Other conditions triggered by the progression of AD include psychosis, sleep disorders, epilepsy, and depression. One important comorbidity is Down’s syndrome, which directly contributes to the severity and rapid progression of AD. The development of new therapeutic strategies for AD includes the repurposing of drugs currently used for the treatment of comorbidities. A better understanding of the influence of comorbidities on the pathogenesis of AD, and the medications used in its treatment, might allow better control of disease progression, and more effective pharmacotherapy. Graphic abstract

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s43440-021-00293-5

Cites

175 of 175 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Influence of diabetes mellitus type 2 on the pathogenesis of Alzheimer's disease
Fig. 1 Influence of diabetes mellitus type 2 on the pathogenesis of Alzheimer's diseaseCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 175 references

Research works printed but not linked: 1

  1. Lawlor B, Segurado R, Kennelly S, Rikkert M, Howard R, Pasquier F, et al. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Med. 2018;15(9):20. · DOI · Paper page

Cited by

See all 64

Metadata

Authors
Maciejewska, K., Czarnecka, K., & Szymański, P.
Affiliations
Medical University of Lodz (PL)
Corresponding author
Szymański, Paweł
Venue
Pharmacological Reports
Published
2021-06-13
Volume
73
Issue
6
Pages
1565-1581
ISSN
  • 1734-1140 (ISSN-L)
  • 2299-5684
OpenAlex
W3171782439
Cited by
64
References
176
Citations by year
2026: 12 · 2025: 17 · 2024: 11 · 2023: 10 · 2022: 12 · 2021: 2
FWCI
1.17
Type
journal article
Language
en
Open access
Licence
Locations
  • Pharmacological Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Narodowym Centrum Nauki (2015/19/B/NZ7/02847)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, comorbidities, hypercholesterolemia, hypertension, atherosclerosis, diabetes mellitus, psychosis, sleep disorders, epilepsy, depression, Down syndrome, drug repurposing, pharmacotherapy, pathogenesis
MeSH terms
Drug Development, Aged, Alzheimer Disease, Animals, Humans, Risk Factors, Disease Progression, Drug Repositioning, Patient Acuity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease. https://app.cochat.ai/papers/10.1007/s43440-021-00293-5
The paper
Maciejewska, K., Czarnecka, K., & Szymański, P. (2021). A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease. Pharmacological Reports. https://doi.org/10.1007/s43440-021-00293-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.